Results 251 to 260 of about 1,877,507 (306)

Comparative Effectiveness and Safety of Inebilizumab Versus Rituximab in AQP4‐IgG‐Positive NMOSD

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Rituximab (anti‐CD20, RTX) and inebilizumab (anti‐CD19, INE) represent B‐cell‐depleting therapies used for aquaporin‐4 antibody‐positive (AQP4‐IgG+) neuromyelitis optica spectrum disorder (NMOSD); however, direct comparative evidence remains limited.
Jie Lin, Binbin Xue, Dewei Xie, Jia Li, Juyuan Pan, Lanbing Zhu, Qiaowen Tong, Jing Lin, Ruofan Zhu, Xu Zhang, Junhui Xia, Xiang Li   +11 more
wiley   +1 more source

Impact of age on graft-versus-host disease and overall survival in pediatric hematopoietic cell transplant recipients. [PDF]

Blood Adv
Nishitani M, Graham RA, Wang T, Devos J, Lee SJ, Spellman SR, Kitko CL, MacMillan ML, DeFilipp Z, Gray AN, Williams KM, Takahashi T, Schoettler ML, Hashem H, Rangarajan HG, Prestidge T, Ringden O, Hamilton BK, Sharma A, Nusrat R, El Jurdi N, Bhatt NS, Duncan CN, Qayed M.   +23 more
europepmc   +1 more source

ABCB1 Polymorphisms Influence on Temozolomide Resistance and Overall Survival in Glioblastoma Patients: A Systematic Review of Clinical Evidence. [PDF]

J Cell Mol Med
De Luca F, Mannino D, Capra AP, Ciappina G, Donato M, Caruso G, Esposito E, Ardizzone A.   +7 more
europepmc   +1 more source

Prognostic Superiority of the White Cell-to-Lymphocyte Ratio (WLR) in Predicting Overall Survival in Patients With Gliomas. [PDF]

In Vivo
Zhang X, Cai G, Zhang H, Zhang Y.
europepmc   +1 more source

Time to treatment initiation and overall survival in osteosarcoma: a national cancer database analysis. [PDF]

Bone Jt Open
Farmer SH, O'Brien AC, Feustel PJ, DiCaprio MR.   +3 more
europepmc   +1 more source

Prediction of Overall Survival in Glioblastoma Using Early Postoperative Reduction in FLAIR Lesion Volume After Gross Total Resection. [PDF]

Cancers (Basel)
Aoki T, Ohno M, Horiguchi G, Yanagisawa S, Kawauchi D, Omura T, Fujii G, Saito K, Hashimoto N, Narita Y.   +9 more
europepmc   +1 more source

Overall survival and prognostic factors in young women with breast cancer: a retrospective cohort study from Southern Thailand. [PDF]

World J Surg Oncol
Khongthong P, Prateepchaiboon T, Ruangsuwan T.   +2 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Overall Survival for Osimertinib Wows

Cancer Discovery, 2023
Abstract The final overall survival (OS) results for the ADAURA trial show that osimertinib reduces the risk of death by 51% in patients with EGFR-mutated non–small cell lung cancer. For stage II or IIIA disease, the 5-year OS was 85% in patients who received osimertinib and 73% in the control group.
openaire   +2 more sources

Concordance index: Surrogacy of progression-free survival for overall survival

Contemporary Clinical Trials, 2021
In oncology clinical trials, the primary endpoint is often time to an event of clinical interest, e.g., time to disease progression or time to death. As a result, progression-free survival (PFS: the time from initiation of treatment till disease progression or death whichever occurs first) and overall survival (OS: the time from initiation of treatment
Yiwei, Fan, Guosheng, Yin
openaire   +2 more sources

Overall survival in older patients with cancer

BMJ Supportive & Palliative Care, 2018
ObjectivesA growing number of patients with cancer are older adults. We sought to identify the predictors for overall survival (OS) in older adults with solid tumour and haematological malignancies between January 2013 and December 2016.MethodsRetrospective cohort study.
Beatrice J Edwards, Xiaotao Zhang, Ming Sun, Juhee Song, Peter Khalil, Meghan Sri Karuturi, Linda Pang, Yunlong Geng, Colin P Dinney, Vicente Valero, Richard E Champlin, Debasish Tripathy   +11 more
openaire   +2 more sources